SCI2042 Final

0.0(0)
Studied by 0 people
call kaiCall Kai
learnLearn
examPractice Test
spaced repetitionSpaced Repetition
heart puzzleMatch
flashcardsFlashcards
GameKnowt Play
Card Sorting

1/246

encourage image

There's no tags or description

Looks like no tags are added yet.

247 Terms

1
New cards

Epidemiology Triangle

Host, Agent, Environment

2
New cards

Host

the organism affected by a disease, which can be human, animal, or plant. It interacts with agents and environments affecting disease occurrence

Example: human, animal, etc.

3
New cards

Agent

any factor that causes disease, including viruses, bacteria, and toxins. It influences the host's health status in the epidemiological process.

Examples: SARS CoV, HIV, parasite, Cholera

4
New cards

Environment

all external or extrinsiv factors: physical, biological, social, economic conditions. Provides opportunity for exposure to disease transmission


Example:

Physical: climate, weather, air, soil, water quallity

Biological: living organisms and vectors → harbor, breed, transmit disease agents (bacteria, rodents)

Socioeconomic/Cultural: human infrastructure, societal influence, population density, sanitation, poverty, cultural habits, healthcare access

5
New cards

Epidemiology

Epi (upon)

Demos (people)

Ology (study)

Study upon people

6
New cards

Infectious Disease Epidemiology

Study of the incidence and Mspread of infectious disease in population overtime

7
New cards

Microbes

organisms seen only with a micrscope

Example: bacteria, algae, protozoa..sometimes virus (debated = nonliving)

8
New cards

Risk factor

Something that increases a person’s chance of getting a disease

Action: smoking

Host: # of people with influenza, # of people vaccinated

9
New cards

South Korea MERS Outbreak

Saudia Arabia MERS outbreak

Korean business man smoked inside airport room

Infected with MERS ——Korea Emergency Department

“Hospital shopping culture” - many hospitals for quality results (free healthcare)

Superspreader (infected 82 ppl)

10
New cards

Incidence

Number of NEW persons who fell ill in the time period DIVIDED by TOTAL population

Time: if not specified, assumed to be 1 year

Use: causation of disease OUTBREAK

Numerator: Number of new cases of disease


11
New cards

Prevalence

ALL cases (old and new) in the total population at a SPECIFIC TIME

Use: Measure disease burden (HIV/AIDS, Hep B)…not used as much in infectious disease

Numerator: Old and new cases

12
New cards

Incidence + Prevalence Shared Denominator

Must take into account of “total population size”

Example: Sweden population = 2x Denmark (# of cases = double Denmark)

13
New cards

Case-Fatality Rate (CFR)

Proportion of people who die out of those who get a specific disease

#of deaths from a disease/ # of cases of disease

Use: seriousness of disease



14
New cards

Mortality Rate

Measure of the frequency of occurrence of death in TOTAL POPULATION caused by a specific disease (specific time interval)

Use: Tracks overall population health (improving/declining)

15
New cards

Attack Rate

Probability of people EXPOSED to an infectious agent becoming ILL

Use: infectivity

Equation: # of people ill / # of people at risk of illness


16
New cards

Basic Reproductive Rate (R0) Defintion

Average # of persons directly infected by infectious cases (during the infectious period) entering a TOTALLY SUSCEPTIBLE POPULATION (no immunity)

Use: measures probability of spread when NEW DISEASE enters population

17
New cards

Epidemic

R0>1 - every infected person on average infects ONE or MORE people

18
New cards

Endemic

R0 = 1 - same number of people infected overtime

19
New cards

Disease dies out

R0<1 - less than one person is infected each time…disease dies out

20
New cards

Basic Reproductive Rate (R0) Equation

R0 = beta * k * D

beta = risk of transmission per person (attack rate)

  • Face masks, condoms, hand washing

k = average number of contacts (per time)

  • isolation, closing school

D - duraction of infectivity of infected person

  • specific for disease

  • decrease: early diagnosis + treatment


21
New cards

Herd Immunity

A significant proportion of the population (herd) has been VACCINATED, providing protection for susceptible individuals

22
New cards

Herd Immunity Threshold (HIT)

Minimum proportion (P) of population need to be immunized

Goal: R = 1 ...endemic for stable infectious disease

R = (1-P)R0

P = proportion of immune population…R = 1

P = 1 - (1/R0)

R0 = 5… then vaccine coverage needs to be more than 80%

23
New cards

Incubation Period

Time from infection to SYMPTOM onset

24
New cards

Latent Period

Time between infected to being INFECTIOUS

25
New cards

Generation Time

Time between the generation of INFECTION

  • cannot be observed


26
New cards

Serial Interval

Time between SYMPTOM onset between generation (observable)

27
New cards

Infectious before symptoms onset

Latent period shorter……than incubation period

Greater risk of spread

28
New cards

Symtomatic before infectious

Incubation period shorter…..than latent period

Easier to curb infection

29
New cards

Determing how fast an epidemic grows

Generation time + R0

30
New cards

HIV stands for

Human Immunodeficiency Virus

31
New cards

HIV Family

Retrovirus - single stranded RNA

Subfamily: Lentivirus (Lenti - slow…dormant after getting into host cell)

32
New cards

HIV Outer Membrane

Phospholipid Bilayer ( two layers of fat molecules)

  • Unique structure - takes part of host membrane


33
New cards

GP 120

Spike used to enter host cell

34
New cards

Capsid

Peptide layer surrounding 2 identical single-stranded RNA

35
New cards

Reverse Transcriptase

Use RNA to convert into DNA…used to pass through host membrane

36
New cards

Integrase

insert viral DNA into host cell DNA (CD4)

37
New cards

Protease

Use to cleave long peptide chains for formation of new HIV

38
New cards

CD4 Cell

Helper T Cell, CD4+ lymphocyte

CD4 - general of army…signals for immune response to anCD4 invader

39
New cards

CD4 Count

Normal: 500 - 1500 cells/mm³

Bacteria Pnemonia: below 500 cells/mm³

HIV damage (TB susceptible) - below 300 cells/mm³

Severe HIV damage (parasitic infection susceptible) - equal 200 cells/mm³

AIDS: below 200 cells/mm³


Traditional: start ART 500-250 cells/mm³

Novel: start immediately

40
New cards

HIV Life Cycle

AFRITAB (Africa Tab)

41
New cards

Attachment

GP120 docking protein (spike on HIV) interacts with CD4 receptor

  • Coreceptor interactions - CCR5 and CXCR4 interact specfically


42
New cards

Fusion

HIV enters CD4 cell, dumping its contents

  • Contents: reverse transcriptase, integrase, protease


43
New cards

Reverse Transcriptase

Makes copy from RNA to DNA (double-stranded)

  • Reverse Transcriptase


44
New cards

Integration

Viral DNA integrates with host DNA at the nucleus of CD4 cell

  • Integrase


45
New cards

Transcription

Information making new HIV is released from the nucleus…become LONG CHAINS of protein

46
New cards

Assembly

Packages of information getting ready to leave CD4 cell at plasma membrane

  • Protease - cleave long polypeptides into packages


47
New cards

Budding

Final step of replication, packages pushes itself out of host cell

  • takes host plasma membrane


48
New cards

Mutations in HIV

HIV Reverse Transcriptase - error-prone

  • Creates drug resistance and mutations


49
New cards

Killing CD4 Cell

HIV replicate in host CD4 cell → leads to CD4 cell death

50
New cards

6 Classes of HIV Medication

  1. NRTIs (Nucleoside Reverse Transcriptase Inhibitor)

  2. NNRTIs (Non-nucleoside Reverse Transcriptase Inhibitor)

  3. PIs (Protease Inhibitors)

  4. IIs (Integrase Inhibitors)

  5. Entry Inhibitors (Fusion)

  6. Boosters - Pharmacokinetic Enhances


51
New cards

NRTIs

Nucleoside Reverse Transcriptase Inhibitor

Prevent HIV RNA making HIV DNA

52
New cards

NNRTIs

Non-nucleoside Reverse Transcriptase Inhibitors

Blocking specific PROTEIN used during Reverse Transcription to prevent transcription of HIV DNA

53
New cards

PIs

Protease Inhibitors

Prevent protease enzyme from cutting long chain into packages for new HIV

54
New cards

IIs

Integrase Inhibitors

Attacks integrase protein…prevent attachment of HIV DNA to CD4 DNA

  • Newer class of medication (2007)…pateints with RESISTANCE


55
New cards

Entry Inhibitors (Fusion)

block HIV attaching to CCR5 receptor (co receptor)…cannot dump its contents

56
New cards

Boosters

Pharmacokinetic Enhances

  • Does not interfere with HIV Life Cycle

  • Boosts the strength of other HIV medications


57
New cards

HIV Vaccine

Not available to HIV/AIDS

- error prone -

individual may have many different mutations of HIV

58
New cards

HIV-1

99% of current pandemic

4 distant groups

  • M, N, O, P

    • O, N - geogrpahically limited to Africa

    • M - 9 subtypes (A to K) + CRF

  • Subtypes - geographically limited


59
New cards

Circulating Recombinant Form (CRF)

Recombinant subtypes - Southeast Asia (common A and E)

I and E

55 CRFs

60
New cards

HIV-2

Less virulent - almost asymptomatic

61
New cards

HIV/AIDS Timeline

1981 - diagnosed in a homosexual man in California

  • unusual symptoms - cough, fungal infection, lung pain, pale

  • Diagnosed with PCP (Pneumonia)…only found in elders, infants, cancer-pt

1982 - labeled “gay cancer” “gay plague”

  • New York, SF, LA

1985 - Pandemic


Africa (Black-faced chimpanzee, SIV mutation) → Haiti (West African ties) → Dominican Republic (popular vacation spot) → US (DR common for men having men relation) → global


62
New cards

Berlin Patient

Timothee Brand - “cured” of HIV

Bone marrow transplant for stem cells - natural resistant to HIV/AIDS

63
New cards

Missisipi Baby

2nd successful case - relapsed 4 years after

  • aggressive cocktail therapy (29 hours hold)


64
New cards

Public health problem

Surveillance, condom distribution, needle exchange

65
New cards

Human rights problem

Stigmatization - PLHIV - refused by doctors, fired from jobs, believed to still be infectious on ART

66
New cards

Security Problem

Post-Cold War - security moved away from war...onto nonmilitary threats


67
New cards

Securized Process

  1. Speech Acts

  2. Audience Acceptance

  3. Emergency Measures


MAIN GOAL: desecuritisation


68
New cards

Speech Acts

Top political leader frame issue as security threat

69
New cards

Audience acceptance

Target audience (citizens, lawmakers) accept

Begin to plan reallocating funding for percieved threat

70
New cards

Emergency measures

Compulsory policies, formation of special governmental bodies

Example:

  1. MAP - World Bank’s Multi-Country AIDS Programme

  2. Global Fund - fight AIDS, TB, Malaria

  3. PEPFAR - President’s Emergency Plan for AIDS Relief


71
New cards

AIDS Exceptionalism

TWO WAVES

1980 - 1st initiated by gay community stigmatized (needed exceptional movement)

1996 - ART development, low cost…fall of exceptionalism

2000 - Jan 2006 Al Gore speech about security threat (rise again)

2008 - Global Financial Crisis…backlash and withdraw from funding

72
New cards

Horizontal vs Vertical Health Program

Vertical Program - disease-specific

  • Move HIV towards chronic primary healthcare (reduce stigma)


Horizontal Program - tackle overall health problems, general health services


73
New cards

Project 2030

Moved from 90-90-90 (2020) to 95-95-95 by 2030

  • 2020 not met: 90-81-73

95% of people infected with HIV know they are infected with HIV

95% of people known with HIV receive ART

95% of people who recieve ART achieve viral supression

74
New cards

Influenza Virus Overview

Family: Orthomyxoviridae

Type: A, B, C, D

  • B, C, D - non-human threat (only in animals)

    • C - causes mild illness

    • D - cattle

    • B - less severe (no pandemics)


75
New cards


Influenza A

Causes human pandemics

2 subtypes:

  1. HA - hemagglutinin - H1 to H18

  2. NA - neuraminidase - N1 to N11


76
New cards

Types of HA and NA endemic to HUMANS

HA - H1, H3

NA - N1, N2

—causes seasonal outbreaks—-

77
New cards

Bird + Swine

Sporadic outbreaks…needs mutation to infect humans for pandemic

Example: H5N1, H9N2, H7N7

78
New cards

Influenza B

2 lineages

  1. B/Yamagata

  2. B/Victoria


79
New cards

Antigenetic Drift

small accumlations of mutations

  • leads to small antigenic changes OVERTIME

  • A and B subtypes

  • Seasonal influenza

  • Remains HA NA specific


80
New cards

Antigenetic Shift

Large scale change

  • non-human influenza infects human host

  • REASSORTMENT of animal and human subtype (double/triple reassortment)

  • Influenza A ONLY

  • Pandemic - population has little to no immunity against

    • Example: Asian Influenza (H2N2), Spanish Flu (H1N1), Hong Kong (H3N2)

    • Avian Flu (H5N1)


81
New cards

Hisotry of Influenza

H3N8 - Russian Flu (1889)

H1N1 - Spanish Flu (1918)

H2N2 - Asian Flu….replaced Spanish Flu (1957)

H3N2 - Hong Kong Flu…replaced Asian Flu (1968)

  • H1N1 - resurfaced (1977) recirculates with H3N2

H5N1 - Avian Flu (1997)

  • H1N1 (Swine Flu) - resurfaced (2009)

H7N9 - China outbreak (2013) confined…not pandemic)


82
New cards

Influenza Nomenclature

Type/(sometimes Animal/Person Reside)Location/Strain#/Year (Virus Subtype)


Example:

A/Hong Kong/156/97 (H5N1)

A/Swine/###/2009 (H1N1)

83
New cards

Influenza Outer Envelope + Genetic Material

Sphereical envelope virus - lipid membrane (from host cell)

  • 8 RNA genetic material


84
New cards

M2 + M1

(M2) Ion channel - viral UNCOATING for early replication

(M1) Matrix protein - creates endosome

85
New cards

Glycoprotein spikes (on lipid membrane)

HA - hemaglutinin - receptor binding site for sialic acid

  • Alpha 2.3 linked SA - common in DUCK gut epithelium

    • H5N1 - higher case fatality (pneumonia)

  • Alpha 2.6 linked SA - common in HUMAN upper respiratory (trachael)


NA - Nema - final stage of infection after budding

  • removed SA from both receptors

  • Prevents virus form binding to DYING host cell

  • “release”


86
New cards

Antiviral Drugs for Influenza

  1. Amantadine - M2 interference

  2. Rimantadine - M2 interference

Does not work for Type B

Typa A : 70 - 90% effective


  1. Tamiflu - inhibit NA (2009…newer drug)


87
New cards

H1N1 Pandemic - 2009

Swine Flu

Subtype A

Antigenetic Shift - no immunity to NOVEL virus

Mixing Vessel: Pigs

  • human + avian + swine

Misunderstanding: pig = reason for infectious spread (lead to slaughter)

88
New cards

H1N1 PHEIC

April 2009 - declared

(38 days after 1st oubreak in Mexico → California)

  • ControversialPubli, Ebola: 138 days for PHEIC


89
New cards

Gain-Of-Function Research (GOF)

“Superbug” worries

Recombinant exchange of gene segments

GOF research - acquisition of new function

  • Experiment with recombinants for better preparation

  • Risk: escape from lab (COVID-19 early suspicions)


90
New cards

Coronavirus Family + Types

Family - orthocoronavirinae

Subfamily - coronavirdae


4 types:

  • Alpha and beta coronavirus - infect HUMANS

    • 2 alpha + 2 beta - known corona virus infections

  • Gamma and delta - infect only ANIMALS


91
New cards

SARS-coV 1

2002 - 2003

Beta coronavirus - Severe Acute Respiratory Syndrome

Index case: Guangdong (Southern China)

Intermediate Host - cevic cat + racoon dog

  • culture: eaten for medical reasons (normally resides in rural areas)


Infectivity - similar to COVID-19 (not as rapid rate)

Case Fatality: 7%


92
New cards

MERS-coV

2012

Beta coronavirus - Middle Eastern Respiratory Syndrome

Saudi Arabia - novel beta coronavirus

Intermediate host: camels


Case Fatality: 34.4%

Infectivity: low transmission rate

93
New cards

SARS-coV 2

2019

beta coronavirus subtype


Index Case: Wuhan China (unsure exact source)


Infectivity: rapid spread

Case Fatality: 2%

94
New cards

Spike Proein (S proteins)

targets ACE2 on host cell and DPP-4

95
New cards

ACE 2

Angiotensin-converting enzyme II

ACE2 - highly expressed in the respiratory tract, epithelial in the bronchi, alveoli, and trachea

96
New cards

DPP-4 receptor

MERS-coV spike - binds to dipeptidyl peptidase 4

DDP-4 lower respiratory tract (severe pneumonia)

97
New cards

Remesivir

First FDA approved drug for COVID -19

  • RNA polymerase inhibitor

  • Previously used for Hep C and Ebola


98
New cards

Emergency grant (authorization)

FDA allows certain life saving drug streatment ——-no alternative approved medication

  • benefits outweigh risks


99
New cards

Baricitinib

FDA emergency grant for rheumatoid arthritis for HOSPITALIZED patients

100
New cards

Molnupiravir


developed by Merck

  • RNA Polymerase (mild to moderate risk)